tradingkey.logo

Tivic Health Systems Inc

TIVC
查看詳細走勢圖
1.890USD
0.000
收盤 12/24, 13:00美東報價延遲15分鐘
3.14M總市值
虧損本益比TTM

Tivic Health Systems Inc

1.890
0.000
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

0.00%

5天

-0.53%

1月

+9.88%

6月

-51.79%

今年開始到現在

-67.89%

1年

-69.94%

查看詳細走勢圖

TradingKey Tivic Health Systems Inc股票評分

單位: USD 更新時間: 2025-12-24

操作建議

Tivic Health Systems Inc當前公司基本面數據相對非常健康,增長潛力很大。當前估值合理,在醫療設備與耗材行業排名157/206位。機構持股佔比非常高,中期看,股價處於下降通道。近一個月,市場表現較強,基本面評分較高,但較強的走勢沒有得到技術面的印證。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Tivic Health Systems Inc評分

相關信息

行業排名
157 / 206
全市場排名
500 / 4562
所屬行業
醫療設備與耗材

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 0 分析師
--
評級
--
目標均價
--
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Tivic Health Systems Inc亮點

亮點風險
Tivic Health Systems, Inc. is a diversified therapeutics company, with complementary bioelectronic and biologic product candidates in its clinical pipeline. It harnesses the power of the immune and autonomic nervous systems to fight disease and restore health. It takes a multi-pronged approach to treating diseases caused by immune dysregulation and dysautonomia. The complement of bioelectronic and biologic medicines allows it to target disorders and disease via both neural pathways and molecular approaches. Its commercial product, ClearUP, is clinically proven to treat sinus pain and pressure. ClearUP is available through online retailers and commercial distributors. It also has worldwide exclusive license rights to the late-stage Toll-like Receptor 5 (TLR5) agonist Entolimod for the treatment of acute radiation syndrome (ARS). In addition, it has an exclusive option to license five additional indications and clinical use cases for Entolimod and its derivative, Entalasta.
業績增長期
公司處於發展階段,最新年度總收入780.00K美元
估值高估
公司最新PE估值-0.01,處於3年歷史高位
機構加倉
最新機構持股44.96K股,環比增加11.62%
先鋒集團持倉
明星投資者先鋒集團持倉,最新持倉1.94K股

Tivic Health Systems Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Tivic Health Systems Inc簡介

Tivic Health Systems, Inc. is a diversified therapeutics company, with complementary bioelectronic and biologic product candidates in its clinical pipeline. It harnesses the power of the immune and autonomic nervous systems to fight disease and restore health. It takes a multi-pronged approach to treating diseases caused by immune dysregulation and dysautonomia. The complement of bioelectronic and biologic medicines allows it to target disorders and disease via both neural pathways and molecular approaches. Its commercial product, ClearUP, is clinically proven to treat sinus pain and pressure. ClearUP is available through online retailers and commercial distributors. It also has worldwide exclusive license rights to the late-stage Toll-like Receptor 5 (TLR5) agonist Entolimod for the treatment of acute radiation syndrome (ARS). In addition, it has an exclusive option to license five additional indications and clinical use cases for Entolimod and its derivative, Entalasta.
公司代碼TIVC
公司Tivic Health Systems Inc
CEOErnst (Jennifer)
網址https://tivichealth.com/

常見問題

Tivic Health Systems Inc(TIVC)的當前股價是多少?

Tivic Health Systems Inc(TIVC)的當前股價是 1.890。

Tivic Health Systems Inc 的股票代碼是什麼?

Tivic Health Systems Inc的股票代碼是TIVC。

Tivic Health Systems Inc股票的52週最高點是多少?

Tivic Health Systems Inc股票的52週最高點是15.640。

Tivic Health Systems Inc股票的52週最低點是多少?

Tivic Health Systems Inc股票的52週最低點是1.470。

Tivic Health Systems Inc的市值是多少?

Tivic Health Systems Inc的市值是3.14M。

Tivic Health Systems Inc的淨利潤是多少?

Tivic Health Systems Inc的淨利潤為-5.66M。

現在Tivic Health Systems Inc(TIVC)的股票是買入、持有還是賣出?

根據分析師評級,Tivic Health Systems Inc(TIVC)的總體評級為--,目標價格為--。

Tivic Health Systems Inc(TIVC)股票的每股收益(EPS TTM)是多少

Tivic Health Systems Inc(TIVC)股票的每股收益(EPS TTM)是-322.802。
KeyAI